TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23424237

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily with bendroflumethiazide 1.25 mg (CB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril 50 mg twice daily with placebo (CP)
Number of subjects: 0
Study: 21894078

Group type: EXPERIMENTAL
Intervention: 100 mg Tramadol mixed with 20 ml of sugar syrup
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 100 mg Tramadol
Number of subjects: 121
Study: 19165648

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 925

Group type: COMPARATOR
Intervention: Diclofenac 50 mg twice daily
Number of subjects: 925
Study: 17115390

Group type: EXPERIMENTAL
Intervention: 0.2 per cent glyceryl trinitrate (GTN) ointment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo ointment (petroleum jelly)
Number of subjects: 82
Study: 15209320

Group type: EXPERIMENTAL
Intervention: Expected Increase
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Expected Similar
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Increase
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Similar
Number of subjects: 40
Study: 11573042

Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 179

Group type: COMPARATOR
Intervention: No drains placed
Number of subjects: 179
Study: 9573911

Group type: EXPERIMENTAL
Intervention: Educational program (1 day per week for 6 weeks)
Number of subjects: 29
Study: 8169417

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for 10 days
Number of subjects: 43

Group type: COMPARATOR
Intervention: Antimicrobial treatment alone
Number of subjects: 43
Study: 2901037

Group type: EXPERIMENTAL
Intervention: Single perioperative course of adjuvant combination chemotherapy beginning within 36 hours of mastectomy
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Six cycles of conventionally timed adjuvant chemotherapy starting 25 to 32 days after operation
Number of subjects: 1229

Group type: EXPERIMENTAL
Intervention: Both the perioperative cycle and the conventionally timed regimen
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Overall survival differences favored the longer treatments
Number of subjects: 1229
Study: 31302092

Group type: EXPERIMENTAL
Intervention: Linked-color imaging (LCI)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Blue-laser imaging (BLI)-bright
Number of subjects: 379

Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 379
Study: 30400688

Group type: EXPERIMENTAL
Intervention: Allergic rhinitis (AR) prevalence in children
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family history of allergic diseases
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to smoking or dust environment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to smoking environment during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pet feeding history
Number of subjects: 0
Study: 27266848

Group type: EXPERIMENTAL
Intervention: 3-Day dorm room isolation intervention
Number of subjects: 590

Group type: COMPARATOR
Intervention: Control group (no isolation)
Number of subjects: 590
Study: 25302462

Group type: EXPERIMENTAL
Intervention: Intravascular low-level laser therapy (LLLT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 23229976

Group type: EXPERIMENTAL
Intervention: Pharmacist‐provided telephone MTM consultation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 20297611

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 50 microg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 100 microg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 200 microg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) (all doses)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS)
Number of subjects: 19
Study: 17636302

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA) of atrial fibrillation
Number of subjects: 221
Study: 15864506

Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil anaesthesia controlled by EEG monitoring (Narcotrend or BIS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propofol-remifentanil anaesthesia controlled by clinical parameters
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Propofol TCI concentrations adjusted according to clinical parameters or EEG target values
Number of subjects: 120
Study: 12412840

Group type: EXPERIMENTAL
Intervention: Marijuana cigarettes (3.95% THC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dronabinol (2.5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0
Study: 10222703

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study: 7503401

Group type: EXPERIMENTAL
Intervention: Formoterol 12 micrograms b.i.d.
Number of subjects: 304

Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms q.i.d.
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study: 2129379

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt‐PA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptokinase (SK)
Number of subjects: 0
Study: 6987024

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 100 mg daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 31923242

Group type: EXPERIMENTAL
Intervention: 300 mg/day of oral Mg++ citrate (n = 66)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo (n = 66)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both groups (Mg++ and placebo)
Number of subjects: 132
Study: 31598912

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 740
Study: 28409402

Group type: EXPERIMENTAL
Intervention: ADT plus tamsulosin for 24 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: ADT for 24 weeks
Number of subjects: 90
Study: 26371261

Group type: EXPERIMENTAL
Intervention: DIAMOND care after implementation (DCA)
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Usual care before implementation (UCB)
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Usual care after implementation (UCA)
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Usual care in comparison clinics (UC)
Number of subjects: 1578
Study: 25281169

Group type: EXPERIMENTAL
Intervention: On-site satisfaction survey
Number of subjects: 457

Group type: COMPARATOR
Intervention: Mail-out satisfaction survey
Number of subjects: 457
Study: 22659994

Group type: EXPERIMENTAL
Intervention: Combination of 16 mg galantamine plus 20 mg memantine
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: 16 mg galantamine alone
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Galantamine (as part of the combination regimen or as mono treatment)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Subgroup of amnestic MCI with presumed AD etiology
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Subgroup of amnestic MCI presumably due to other etiologies
Number of subjects: 232
Study: 20817382

Group type: EXPERIMENTAL
Intervention: Individual motivational interviewing (MI) sessions
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: MI sessions including a significant other (SO)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Individual MI sessions
Number of subjects: 382
Study: 17626700

Group type: EXPERIMENTAL
Intervention: Health Tracker (HT) reports
Number of subjects: 1079

Group type: COMPARATOR
Intervention: HT-nonviewers
Number of subjects: 1079
Study: 15724754

Group type: EXPERIMENTAL
Intervention: FRC Postec bonded with Excite DSC/Variolink II
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FRC Postec bonded with Syntac/Variolink II
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: FRC Postec bonded with Excite DSC/Experimental Self Cure Cement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: C-Post bonded with One Step/Hi-X
Number of subjects: 32

Group type: COMPARATOR
Intervention: ParaPost Fiber White (self-cure control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cosmopost (zirconia post)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Medium region of the root
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cervical root region
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Apical region
Number of subjects: 32
Study: 12471291

Group type: EXPERIMENTAL
Intervention: Physical therapy treatment (McConnell-based)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 65
Study: 9830074

Group type: COMPARATOR
Intervention: Essential oils rinse
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Alcohol-free chlorhexidine (0.12%)
Number of subjects: 32
Study: 8120307

Group type: EXPERIMENTAL
Intervention: Influenza hemagglutinin-diphtheria toxoid conjugate vaccine (HA-D)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Influenza hemagglutinin-subunit vaccine (HA)
Number of subjects: 408
Study: 2571296

Group type: EXPERIMENTAL
Intervention: Rilmenidine 1 mg
Number of subjects: 392

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 392

Group type: COMPARATOR
Intervention: Reference alpha 2‐agonists
Number of subjects: 392
Study: 424690

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Selective vagotomy with pyloroplasty (SV + P)
Number of subjects: 32
Study: 31901705

Group type: EXPERIMENTAL
Intervention: COMBO450 (450 mg of encorafenib QD + 45 mg of binimetinib BID)
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: ENCO300 (300 mg of encorafenib QD)
Number of subjects: 577

Group type: COMPARATOR
Intervention: VEM (960 mg of vemurafenib BID)
Number of subjects: 577
Study: 30640775

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of TXA 100 mg/1 mL
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of TXA 100 mg/1 mL in anticoagulant subgroup
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo (saline) in anticoagulant subgroup
Number of subjects: 131
Study: 28796809

Group type: EXPERIMENTAL
Intervention: DP‐EES (everolimus-eluting stent)
Number of subjects: 455

Group type: COMPARATOR
Intervention: DP‐SES (sirolimus-eluting stent)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: DP‐EES
Number of subjects: 455

Group type: COMPARATOR
Intervention: DP‐SES
Number of subjects: 455
Study: 25761916

Group type: EXPERIMENTAL
Intervention: Enhanced dissemination strategy of the Go Sun Smart (GSS) program
Number of subjects: 909

Group type: COMPARATOR
Intervention: Basic dissemination strategy of the Go Sun Smart (GSS) program
Number of subjects: 909

Group type: EXPERIMENTAL
Intervention: Greater recall of messages (regardless of level of implementation)
Number of subjects: 909
Study: 23638986

Group type: EXPERIMENTAL
Intervention: Microneedling-assisted PDT (MN-PDT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional methyl aminolevulinate (MAL) PDT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both MN-PDT and conventional MAL-PDT
Number of subjects: 10
Study: 21306698

Group type: EXPERIMENTAL
Intervention: Laparoscopic sacral colpopexy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Total vaginal mesh
Number of subjects: 108
Study: 19491837

Group type: EXPERIMENTAL
Intervention: Baclofen (3 x 20 mg) during PPI treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo during PPI treatment
Number of subjects: 27
Study: 19396451

Group type: EXPERIMENTAL
Intervention: Ligasure diathermy hemorrhoidectomy under spinal anesthesia
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional diathermy hemorrhoidectomy under spinal anesthesia
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Ligasure diathermy hemorrhoidectomy under local anesthesia
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional diathermy hemorrhoidectomy under local anesthesia
Number of subjects: 74
Study: 15240612

Group type: EXPERIMENTAL
Intervention: High-protein diet (40% carbohydrate, 30% protein)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Standard protein diet (55% carbohydrate, 15% protein)
Number of subjects: 32
Study: 12899366

Group type: EXPERIMENTAL
Intervention: Duchenne smiling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Duchenne smiling (low-level)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-Duchenne smiling (high-level)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific smile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lips pressing
Number of subjects: 0
Study: 10335040

Group type: EXPERIMENTAL
Intervention: Neuropeptide Y levels in patients with variant angina before, during, and after hyperventilation test
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Thromboxane B2 levels in patients with variant angina during hyperventilation test
Number of subjects: 38

Group type: COMPARATOR
Intervention: Neuropeptide Y levels in patients with chronic stable angina pectoris
Number of subjects: 38

Group type: COMPARATOR
Intervention: Thromboxane B2 levels in patients with chronic stable angina pectoris
Number of subjects: 38

Group type: COMPARATOR
Intervention: Neuropeptide Y levels in healthy controls
Number of subjects: 38

Group type: COMPARATOR
Intervention: Thromboxane B2 levels in healthy controls
Number of subjects: 38
Study: 8602379

Group type: EXPERIMENTAL
Intervention: clarithromycin 250 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: doxycycline 100 mg twice/day for 7 days
Number of subjects: 40
Study: 2813982

Group type: EXPERIMENTAL
Intervention: Ambroxol 75 mg once a day after breakfast for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1069366

Group type: EXPERIMENTAL
Intervention: i.v. pulse doses of 13‐nle‐m (0.05, 0.1, 0.2, and 0.4 mug/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: i.v. bolus injections of 0.6 mug/kg pentagastrin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: i.v. infusions of 13‐nle‐m (0.1, 0.2, and 0.4 mug/kg‐h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: i.v. pulse dose of 0.1 mug/kg 13‐nle‐m with concomitant atropine
Number of subjects: 19
Study: 11450926

Group type: EXPERIMENTAL
Intervention: Outreach visit
Number of subjects: 38

Group type: COMPARATOR
Intervention: Offer of an outreach visit
Number of subjects: 38

Group type: COMPARATOR
Intervention: Acceptance of a visit
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Metronidazole use
Number of subjects: 38
Study: 30500351

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 29493409

Group type: EXPERIMENTAL
Intervention: Brief Cognitive-Behavioral Therapy (CBT)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 176
Study: 26611499

Group type: EXPERIMENTAL
Intervention: Tailored education
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Untailored education
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 24709026

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) school meals
Number of subjects: 834

Group type: COMPARATOR
Intervention: Control (usual packed lunches)
Number of subjects: 834
Study: 22460459

Group type: EXPERIMENTAL
Intervention: Melatonin 2x5 mg daily
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20131565

Group type: EXPERIMENTAL
Intervention: Breast Cancer Recovery Program (exercise and relaxation program)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Health professionals' recommendations (control)
Number of subjects: 32
Study: 17601560

Group type: EXPERIMENTAL
Intervention: Morning dosing of sustained-release morphine sulfate
Number of subjects: 45

Group type: COMPARATOR
Intervention: Evening dosing of sustained-release morphine sulfate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both morning and evening dosing
Number of subjects: 45
Study: 15754238

Group type: EXPERIMENTAL
Intervention: Graf's ligamentoplasty
Number of subjects: 52

Group type: COMPARATOR
Intervention: Dorsoventral fusion
Number of subjects: 52
Study: 11890840

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Higher LDL cholesterol levels
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Reduction in LDL cholesterol levels
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Higher total and LDL cholesterol levels
Number of subjects: 1037

Group type: COMPARATOR
Intervention: High-density lipoprotein cholesterol and triglyceride levels
Number of subjects: 1037
Study: 9521487

Group type: EXPERIMENTAL
Intervention: L-arginine (30 g or 6 g, intravenous infusion for 30 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-arginine (10 microM-2.5 mM, in vitro preincubation)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 20
Study: 7543691

Group type: EXPERIMENTAL
Intervention: Human albumin (6 g per liter of extracted liquid)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dextran 70 (6 g per liter of extracted liquid)
Number of subjects: 16
Study: 2650701

Group type: EXPERIMENTAL
Intervention: Intraarticular bupivacaine (Marcaine)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 79
Study: 1071676

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study: 30923816

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) treatment for 8-16 weeks
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (G/P) treatment
Number of subjects: 2369
Study: 30325178

Group type: EXPERIMENTAL
Intervention: Pegvisomant (PEGV), average daily dose increased from 12.8 mg (year 1) to 18.9 mg (year 10)
Number of subjects: 2090

Group type: EXPERIMENTAL
Intervention: Pegvisomant (PEGV)
Number of subjects: 2090
Study: 26797837

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiochemotherapy (50 Grays over six weeks and four cycles of mFOLFOX6 chemotherapy)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 70
Study: 23650880

Group type: EXPERIMENTAL
Intervention: Small gauze dressings (n=19)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Large gauze dressings (n=22)
Number of subjects: 41
Study: 22203835

Group type: EXPERIMENTAL
Intervention: High-fructose diet (150g per day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High-glucose diet (150g per day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Balanced weight-maintaining diet
Number of subjects: 20
Study: 19417620

Group type: EXPERIMENTAL
Intervention: Electrocardiograms in patients over 50 years of age
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Electrocardiograms in patients with risk factors (age > 65, history of heart failure, high cholesterol, angina, myocardial infarction, severe valvular disease)
Number of subjects: 1149

Group type: COMPARATOR
Intervention: Electrocardiograms in patients without risk factors
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Model sensitivity
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Age greater than 65 years
Number of subjects: 1149
Study: 17126918

Group type: EXPERIMENTAL
Intervention: Ribosomal immunotherapy (one tablet a day, 8 days a month for 3 months)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (same dosage for the same period)
Number of subjects: 160
Study: 15962569

Group type: EXPERIMENTAL
Intervention: Eruption times of permanent teeth in females
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Eruption times of permanent teeth in males
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Eruption sequence of teeth
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Comparison of tooth eruption in both jaws
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 1396
Study: 11313088

Group type: COMPARATOR
Intervention: Antidepressants (pharmacotherapy)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Combined therapy (antidepressants + 16 sessions of Short Psychodynamic Supportive Psychotherapy)
Number of subjects: 167
Study: 9138281

Group type: EXPERIMENTAL
Intervention: 25 mg, 100 mg or 300 mg lamivudine daily for 6 months
Number of subjects: 13
Study: 8184968

Group type: EXPERIMENTAL
Intervention: ANP (2.0 pmol.kg‐1.min‐1 for 5 h) + BNP (2.0 pmol.kg‐1.min‐1 for 2 h)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP + BNP
Number of subjects: 8
Study: 2908102

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.3 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.6 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Bromocriptine 2.5 mg (Control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.3-0.6 mg (repeated administration)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cabergoline 0.6 mg (increased dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Cabergoline (any dose)
Number of subjects: 8
Study: 29210921

Group type: EXPERIMENTAL
Intervention: Probiotics administration during late pregnancy and first 6 months of life
Number of subjects: 1223

Group type: COMPARATOR
Intervention: Placebo administration during late pregnancy and first 6 months of life
Number of subjects: 1223
Study: 28175315

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg) co-administered with rifampicin, isoniazid, and pyrazinamide in HIV co-infected patients on efavirenz-based ART
Number of subjects: 58

Group type: COMPARATOR
Intervention: Moxifloxacin alone (single dose) after TB treatment completion
Number of subjects: 58